RESUMO
Reversible cerebral vasoconstriction syndrome (RCVS) is characterized by acute and usually severe headache related to multifocal vasoconstriction of cerebral arteries, reversible within 3 months. About 10% of RCVS are pregnancy-related, but only three cases of antepartum RCVS have been described. We report the case of a 26-year-old pregnant woman who presented at 36 weeks gestation with antepartum RCVS. Delivery was managed by cesarean section under general anesthesia. Though she developed focal neurologic deficits on the first postoperative day, these resolved at hospital discharge. This case highlights pre- and post-partum multidisciplinary management including cesarean section under general anesthesia.
Assuntos
Anestesia Geral/métodos , Cesárea/métodos , Cefaleia/terapia , Transtornos Puerperais/terapia , Vasoconstrição/fisiologia , Adulto , Artérias Cerebrais/fisiopatologia , Feminino , Humanos , Gravidez , SíndromeRESUMO
INTRODUCTION: Home care management offers a suitable alternative to hospitalization for management of preterm premature rupture of membranes (PPROM). Eligibility criteria have not been clearly established. Our aim was to determine predictive factors of complication during home care management of PPROM in order to define optimal eligibility criteria. MATERIAL AND METHODS: Retrospective cohort study of all women with singleton pregnancies with PPROM managed as outpatients between 2009 and 2015. Complications were defined as the occurrence of one of these events: fetal death, placental abruption, umbilical cord prolapse, delivery outside maternity hospital, neonatal death. RESULTS: In all, 187 women with PPROMs were managed as outpatients, of whom 12 had a complication (6.4%). In the "complication" group, gestational age at diagnosis (P = 0.006) and at delivery (P < 0.001) were lower, with no difference in latency between these two events. Three criteria significantly increased the risk for a severe complication: PPROM occurring before 26 weeks (P = 0.008), non-cephalic fetal presentation (P = 0.02) and oligoamnios (P = 0.02). When unfavorable criteria were associated with PPROM, the risk was increased (1 criterion, odds ratio [OR] 1.6; 2 criteria, OR 6.9 and 3 criteria, OR 32.8). CONCLUSIONS: Combination of these three criteria is an indication for conventional hospitalization to limit maternal and fetal morbidity. When two criteria are combined, home care should be discussed for each case. If only one unfavorable criteria is present, outpatient management is suitable. To validate these results, a prospective randomized study should be conducted.
Assuntos
Assistência Ambulatorial , Contraindicações , Ruptura Prematura de Membranas Fetais/terapia , Serviços de Assistência Domiciliar , Adulto , Feminino , Seguimentos , Idade Gestacional , Humanos , Gravidez , Estudos Retrospectivos , Resultado do TratamentoRESUMO
PURPOSE: Face presentation is rare. Its risk factors are debated and its mechanism is practically unknown. The objectives of the study were to determine the prenatal factors associated with face presentation at delivery and discuss the mechanism by which it occurs. METHODS: Retrospective case-control study including all cases of face presentation of infants born at a gestational age between 22 and 42 weeks of gestation over a 16 year period. For each case, we selected three control women who gave birth the same day. RESULTS: During the study period, there were 64 cases of face presentation (incidence: 0.8 per 1000 births), which we compared with 191 controls. After logistic regression, the four factors most closely associated with delivery in face presentation were twin pregnancy [OR 25.8 (4.7-141.8)], birth weight <2500 g [OR 8.9 (2.1-38.0)], polyhydramnios [OR 7.1 (2.0-25.2)], and multiparity [OR 3.6 (1.5-8.6)]. CONCLUSION: These factors are all associated with a reduction in the uterine constraints on fetal attitude. This may play a role in the mechanism resulting in face presentation.
Assuntos
Peso ao Nascer , Apresentação no Trabalho de Parto , Poli-Hidrâmnios/epidemiologia , Adulto , Estudos de Casos e Controles , Feminino , Idade Gestacional , Humanos , Lactente , Recém-Nascido , Modelos Logísticos , Gravidez , Estudos Retrospectivos , Fatores de Risco , Adulto JovemRESUMO
PURPOSE: Cesarean deliveries of multiple pregnancies are associated with a high risk of hemorrhage. The aim of this study is to evaluate the efficacy of carbetocin administered systematically during cesarean deliveries of multiple pregnancies. METHODS: Single-center retrospective before-and-after study comparing the use of carbetocin to that of oxytocin during cesareans during two consecutive 6-month periods. A composite variable was predefined as the principal endpoint: any one or more of bleeding ≥1,500 mL, transfusion, hemoglobin reduction of 4 g/dL or more or operative intervention (surgery, embolization). RESULTS: In an intention-to-treat analysis, the comparison of the two groups (n = 24 before and n = 39 after) showed no difference for the occurrence of the composite variable (16.7 vs. 15.4 %, p = 0.89). Nor did the per-protocol analysis (n = 24 before and n = 27 after) differ for it (16.7 vs. 14.8 %, p = 0.86). Moreover, none of the secondary outcome measures studied-moderate blood loss, prescription of sulprostone, cell-saver use, and intravenous iron infusion-differed significantly between the two periods. CONCLUSION: In our population of multiple pregnancies delivered by cesarean, carbetocin did not appear more effective than oxytocin in preventing severe postpartum hemorrhage.
Assuntos
Cesárea/efeitos adversos , Cesárea/métodos , Ocitócicos/uso terapêutico , Ocitocina/análogos & derivados , Gravidez Múltipla , Adulto , Feminino , Humanos , Ocitocina/uso terapêutico , Hemorragia Pós-Parto/epidemiologia , Hemorragia Pós-Parto/prevenção & controle , Hemorragia Pós-Parto/terapia , Gravidez , Estudos Retrospectivos , Resultado do TratamentoAssuntos
Doenças do Desenvolvimento Ósseo/diagnóstico , Doenças do Desenvolvimento Ósseo/genética , Mutação , Receptor Tipo 2 de Fator de Crescimento de Fibroblastos/genética , Alelos , Substituição de Aminoácidos , Osso e Ossos/diagnóstico por imagem , Osso e Ossos/patologia , Códon , Feminino , Humanos , Fenótipo , Ultrassonografia Pré-NatalRESUMO
OBJECTIVE: To provide national guidelines for the management of women with severe pre-eclampsia. DESIGN: A consensus committee of 26 experts was formed. A formal conflict-of-interest (COI) policy was developed at the onset of the process and enforced throughout. The entire guidelines process was conducted independently of any industrial funding. The authors were advised to follow the principles of the Grading of Recommendations Assessment, Development and Evaluation (GRADE®) system to guide assessment of quality of evidence. The potential drawbacks of making strong recommendations in the presence of low-quality evidence were emphasised. METHODS: The last SFAR and CNGOF guidelines on the management of women with severe pre-eclampsia were published in 2009. The literature is now sufficient for an update. The aim of this expert panel guidelines is to evaluate the impact of different aspects of the management of women with severe preeclampsia on maternal and neonatal morbidities separately. The experts studied questions within 7 domains. Each question was formulated according to the PICO (Patients Intervention Comparison Outcome) model and the evidence profiles were produced. An extensive literature review and recommendations were carried out and analysed according to the GRADE® methodology. RESULTS: The SFAR/CNGOF experts panel provided 25 recommendations: 8 have a high level of evidence (GRADE 1+/-), 9 have a moderate level of evidence (GRADE 2+/-), and for 7 recommendations, the GRADE method could not be applied, resulting in expert opinions. No recommendation was provided for 3 questions. After one scoring round, strong agreement was reached between the experts for all the recommendations. CONCLUSIONS: There was strong agreement among experts who made 25 recommendations to improve practices for the management of women with severe pre-eclampsia.
Assuntos
Pré-Eclâmpsia , Feminino , Humanos , Recém-Nascido , Pré-Eclâmpsia/terapia , GravidezRESUMO
OBJECTIVE: To determine the diagnostic accuracy and optimal threshold of the spot protein-to-creatinine ratio (PCR) compared to the gold standard, 24-hour proteinuria (24HP) in patients with suspected pre-eclampsia. METHODS: A prospective observational study was performed from June 2015 to May 2017 consisting of patients hospitalized for suspected pre-eclampsia in a tertiary care referral center. To compare the two diagnostic tests, a spot urine sample was obtained to perform the PCR before starting the collection of the 24HP. Only patients who had both tests were analyzed. RESULTS: In total, 148 patients (216 samples) were included. The two tests were highly correlated (r=0.80, P<0.001). The receiver operating characteristic curve analysis and the area under the curve (AUC=0.92) highlighted the accuracy of PCR in diagnosing significant proteinuria and thus pre-eclampsia. The optimal cut-off using the Liu method was 56.9 mg/mmol (sensitivity=79.3%, specificity=91.5%). CONCLUSION: The results suggest that PCR could replace 24HP when diagnosing proteinuria in pre-eclampsia. Moreover, it is a simple test, easy to realize and standardize, and cheap with no need for systematic hospitalization. The best cut-off should be chosen by thinking about the risks for adverse maternal and/or fetal outcomes. The test may help to optimize medical care in pre-eclampsia worldwide.
Assuntos
Creatinina/urina , Pré-Eclâmpsia/diagnóstico , Proteinúria/diagnóstico , Adulto , Testes Diagnósticos de Rotina , Feminino , Humanos , Pré-Eclâmpsia/urina , Valor Preditivo dos Testes , Gravidez , Estudos Prospectivos , Proteinúria/urina , Curva ROCRESUMO
OBJECTIVE: To evaluate the use of the intracervical balloon compared with locally applied prostaglandins for cervical ripening for induction in patients with preterm premature rupture of membranes. METHODS: Monocentric, retrospective (from 2002 to 2017) observational cohort study of singleton pregnancies complicated by preterm premature rupture of membranes and induced between 34 and 37 weeks. The primary outcome measure was balloon catheter efficiency evaluated by Cesarean section rate. Secondary outcomes were : interval from induction to delivery, labor duration, oxytocin use, intrauterine infection rate, maternal complications (i.e., postpartum hemorrhage and endometritis), and neonatal complications. RESULTS: 60 patients had cervical ripening with prostaglandins alone and 58 had balloon catheter. Demographic characteristics were similar between the groups, except for induction term and neonatal weight. There was not a significant difference in occurrence of Cesarean section rate (p = 0.14). Nor were there significant differences in time from induction to birth (p = 0.32) or in intrauterine infection rate (p = 0.95). Labor duration was shorter (p = 0.006) and total oxytocin dose lower (p = 0.005) in patients induced by prostaglandins alone. Concerning neonatal outcomes, there were more transfers to intensive care (p = 0.008) and more respiratory distress (p = 0.005) among newborns induced by prostaglandins. CONCLUSION: Compared with locally applied prostaglandins, balloon catheter induction is not associated with an increase of Cesarean section rate in patients with preterm premature rupture of membranes.
Assuntos
Maturidade Cervical/fisiologia , Ruptura Prematura de Membranas Fetais , Trabalho de Parto Induzido/instrumentação , Trabalho de Parto Induzido/métodos , Adulto , Cateterismo/instrumentação , Cateterismo/métodos , Cesárea/estatística & dados numéricos , Estudos de Coortes , Feminino , Idade Gestacional , Humanos , Recém-Nascido , Trabalho de Parto Induzido/efeitos adversos , Ocitocina/administração & dosagem , Gravidez , Prostaglandinas/administração & dosagem , Prostaglandinas/efeitos adversos , Infecções do Sistema Genital/epidemiologia , Estudos Retrospectivos , Doenças Uterinas/microbiologiaRESUMO
Preeclampsia (PE), a specific complication of pregnancy, is one of the most frequent causes of maternal and fetal morbidity and mortality in the world. Recently, PE risk calculation algorithms allowing early detection of PE in the first trimester of pregnancy have been described. The aim of early detection would be to rapidly introduce an effective preventive treatment. The aim of our work is to study the different preventive treatments through the literature. Aspirin has some efficiency and reduces the risk of PE from 10 to 24%. It is most effective when the dose exceeds 75mg and when introduced before 16 gestational age. Early introduction of aspirin mainly prevents severe and preterm PE. Low molecular weight heparin (LMWH) and vitamin D appear to be promising therapy for PE but further research is required. Calcium administered at 1g/day reduces the risk of PE especially to patients with low baseline calcium intake. A low dose of calcium could also reduce the risk of PE but this must be confirmed. Other preventive measures (antioxidants, nitric oxide, progesterone, rest, exercise) do not reduce the incidence of PE.
Assuntos
Pré-Eclâmpsia/prevenção & controle , Anticoagulantes , Feminino , Humanos , Inibidores da Agregação Plaquetária/uso terapêutico , Guias de Prática Clínica como Assunto , GravidezRESUMO
Human placental development is characterized by invasion of extravillous cytotrophoblasts (EVCTs) into the uterine wall during the first trimester of pregnancy. Peroxisome proliferator-activated receptor γ (PPARγ) plays a major role in placental development, and activation of PPARγ by its agonists results in inhibition of EVCT invasion in vitro. To identify PPARγ target genes, microarray analysis was performed using GeneChip technology on EVCT primary cultures obtained from first-trimester human placentas. Gene expression was compared in EVCTs treated with the PPARγ agonist rosiglitazone versus control. A total of 139 differentially regulated genes were identified, and changes in the expression of the following 8 genes were confirmed by reverse transcription-quantitative polymerase chain reaction: a disintegrin and metalloproteinase domain12 (ADAM12), connexin 43 (CX43), deleted in liver cancer 1 (DLC1), dipeptidyl peptidase 4 (DPP4), heme oxygenase 1 (HMOX-1), lysyl oxidase (LOX), plasminogen activator inhibitor 1 (PAI-1) and PPARγ. Among the upregulated genes, lysyl oxidase (LOX) was further analyzed. In the LOX family, only LOX, LOXL1 and LOXL2 mRNA expression was significantly upregulated in rosiglitazone-treated EVCTs. RNA and protein expression of the subfamily members LOX, LOXL1 and LOXL2 were analyzed by absolute RT-qPCR and western blotting, and localized by immunohistochemistry and immunofluorescence-confocal microscopy. LOX protein was immunodetected in the EVCT cytoplasm, while LOXL1 was found in the nucleus and nucleolus. No signal was detected for LOXL2 protein. Specific inhibition of LOX activity by ß-aminopropionitrile in cell invasion assays led to an increase in EVCT invasiveness. These results suggest that LOX, LOXL1 and LOXL2 are downstream PPARγ targets and that LOX activity is a negative regulator of trophoblastic cell invasion.
Assuntos
Perfilação da Expressão Gênica , PPAR gama/metabolismo , Placentação , Proteína-Lisina 6-Oxidase/genética , Proteína-Lisina 6-Oxidase/metabolismo , Trofoblastos/citologia , Aminoácido Oxirredutases/genética , Aminoácido Oxirredutases/metabolismo , Aminopropionitrilo/farmacologia , Feminino , Regulação Enzimológica da Expressão Gênica/efeitos dos fármacos , Humanos , Placenta/efeitos dos fármacos , Placenta/enzimologia , Gravidez , Primeiro Trimestre da Gravidez/genética , Primeiro Trimestre da Gravidez/fisiologia , Transporte Proteico/efeitos dos fármacos , Proteína-Lisina 6-Oxidase/antagonistas & inibidores , Rosiglitazona , Tiazolidinedionas/farmacologia , Trofoblastos/efeitos dos fármacosRESUMO
We report four cases of grade 2 and 3 endo-metrial adenocarcinomas managed conservatively in order to preserve fertility. In the literature, seven other cases have been reported. We discuss the management of these cases and compared the carcinologic and fertility outcomes with fertility-sparing management of grade 1 endometrial adenocarcinoma.